OncoDxRx has eight transformative liquid biopsy pipelines currently are in different phases of research and development, validation and commercialization, with PGA (Patient-derived Gene expression-informed Anti-cancer drug efficacy) assays to be launched shortly. Other technologies include MRD, multi-cancer early detection as well as DNA repair activity measurement and cancer drug discovery. “OncoDxRx will thus secure its forefront position to deal with cancer patients in all stages, whether in the context of cancer screening and prevention or in the context of treatment selection, recurrence monitoring or drug discovery.” The company said in the statement.